JPMorgan CEO Jamie Dimon expressed concern about inflation and predicts higher interest rates for longer than expected. He highlighted secular drivers such as the energy transition, geopolitical issues, infrastructure spending, and large deficits/debt levels. The favorable period for inflation in developed nations from 2009 to 2021 is likely over.
Biotech is one of the most exciting industries to invest in right now. Companies have drugs on the market worth billions and continue to strive to produce the newest and best treatments in modern medicine.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
This company offers growth, high yield, and dividend growth.
AbbVie is bolstering its psychiatry pipeline with an acquisition. The biotech it's acquiring is developing psychedelic-adjacent drugs.
Since 1928, there have been 25 bear markets, or declines in the S&P 500 of 20% or more, according to Yardeni Research. Market corrections have been far more common.
AbbVie's lead drug Humira lost its patent-protected market exclusivity in the U.S. last year. Despite shrinking Humira revenues, AbbVie's first-quarter sales grew thanks to more recently launched blockbusters.
Finding equities with the potential for steady, long-term development is crucial. These seven prospects span a variety of industries and offer solid arguments for long-term investment.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?